Dispatch Biotherapeutics
Immunotherapy for Solid Tumors
- Business Model
- B2B
- Website
- dispatchbio.com
- Total Funding
- $106.0M
- Last Round
- $100.0M Series AJul 2025
- Rounds
- 2
About
Clinical-stage immunotherapy company developing the Flare platform to expand curative potential of cancer treatments for solid tumors.
Summary
Dispatch Biotherapeutics is a Biotech company. It has raised $106.0M in total across 2 rounds, most recently a $100.0M Series A round in Jul 2025. Investors include Parker Institute for Cancer Immunotherapy, ARCH Venture Partners and Bristol Myers Squibb.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform